In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. Ubiquitin-relevant proteins that control the stability of critical super enhancer-mediated proteins https://irvingl766yis8.wikilowdown.com/user